Please login to the form below

Not currently logged in
Email:
Password:

Dave Lemus joins Proteros as an executive board member

He joins the German biotech’s board from Medigene

Proteros, a private biotech based in Germany, has appointed Dave Lemus as an executive board member, chief operating officer and chief financial officer of Proteros Biostructures.

Additionally, he will serve in the role of non-executive board chairman of Proteros USA, the company’s newly-formed subsidiary in the US, where he will be based.

He said: “I am excited to assist the company in attaining its ambitious global goals and look forward to helping enable Proteros achieve its next stage of development.

“Proteros’ science base and numerous active collaborations with virtually all of the global pharmaceutical and biotech industry’s major players, provides a tremendous base from which to grow from.”

Prior to his new roles, Lemus was chief operating officer and chief financial officer of Medigene, assisting in its transformation into an immunotherapy-based company through the establishment of strategic partnerships.

He has also held roles with MorphoSys and Hoffman La Roche.

Torsten Neuefeind, chief executive officer of Proteros, said: “I am delighted to have Dave on board during what is a phase of rapid development and progress at Proteros.

“We have greatly appreciated his contributions over the last years in his service on our board, and I sincerely believe he can support us in achieving our goal to become a global leader on technically challenging and novel targets.”

9th January 2018

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics